Maas BiolAB

Maas BiolAB is a biotechnology company dedicated to the development of mitochondrial-targeted neuroprotective treatments. The company focuses on the therapeutic application of cyclosporine to mitigate mitochondrial dysfunction and programmed cell death in acute and chronic neurological conditions. Its lead programs target traumatic brain injury (TBI), stroke, and amyotrophic lateral sclerosis (ALS) by inhibiting the mitochondrial permeability transition pore. Maas BiolAB has established a significant intellectual property portfolio around cyclosporine formulations and has previously partnered with international firms for clinical advancement.